Major Investors Reposition Pharmaceutics International, Inc.
A significant transition has taken place in the healthcare investment landscape as a consortium of investors, including Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Inc., have successfully exited their equity stake in Pharmaceutics International, Inc. (Pii). This change culminated in a noteworthy all-cash transaction involving the sale of Pii to Jabil Inc. (NYSE: JBL), a recognized leader in engineering and manufacturing solutions.
About Pharmaceutics International, Inc.
Pharmaceutics International, Inc. is a contract development and manufacturing organization (CDMO) based in Hunt Valley, Maryland. Renowned for its expertise in aseptic and sterile injectable pharmaceutical products, Pii has been a trusted partner for pharmaceutical clients for nearly 30 years. The company offers an extensive array of formulation capabilities, catering to various dosage forms and specialized drugs.
Operational Expertise and Growth
John Fowler, President and CEO of Pii, expressed immense gratitude towards the investment consortium for their ongoing support. ‘We have considerably appreciated our collaboration with these prominent firms,’ he stated. According to Fowler, the collective expertise of the partners greatly contributed to Pii's strategic scaling and enhancement over the years.
A Bright Future Ahead
With this transition, Pii aims to build upon its existing success by leveraging the resources and operational strengths of Jabil Inc. The firm is optimistic about extending its capabilities and enhancing services with the backing of its new partners, paving the way for future innovations in the pharmaceutical space.
What Sets Pharmaceutics Apart
Pii operates as a privately held CDMO, committed to providing high-quality services to the global pharmaceutical industry. Their offerings extend beyond mere manufacturing; they focus on the entire development process, inclusive of preformulation, formulation testing, clinical, and commercial manufacturing, as well as clinical packaging and analytical services. The company’s sophisticated facilities and state-of-the-art equipment enable them to tackle complex formulations effectively.
Industry Impact of the Transition
This acquisition marks a significant milestone not just for Pii but also for the broader healthcare investment community. As Jabil Inc. takes the reins, it signals a sustained commitment to advancing pharmaceutical manufacturing and development. Stakeholders within the industry are keenly observing how this strategic shift will influence market dynamics and innovation.
About the Investors
Signet Healthcare Partners stands out as a premier provider of growth capital in healthcare sectors, focusing on pharmaceuticals and medical devices. The firm has successfully raised over $600 million and has worked alongside numerous innovative companies to foster growth and drive value.
Athyrium Capital Management specializes in healthcare investment opportunities and manages funds with an impressive $4.6 billion in committed capital, covering a diverse range of healthcare sectors, including biopharma and medical devices.
Hildred Capital is recognized for its focus on operationally intensive investments in middle-market healthcare companies, partnering with teams to stimulate growth and create substantial value.
Meanwhile, Pharmascience Inc. continues to be a formidable force in the pharmaceutical landscape, with a robust presence in over 60 countries. The firm is integral to the manufacturing of both generic and FDA-approved products, contributing significantly to Canada’s pharmaceutical sector.
Frequently Asked Questions
What recent development occurred regarding Pharmaceutics International?
A consortium led by Signet Healthcare Partners announced their exit from Pharmaceutics International, selling the company to Jabil Inc.
Who were the main investors involved in the transition?
The main investors included Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Inc.
What services does Pharmaceutics International provide?
Pii offers contract development and manufacturing services, specializing in aseptic and sterile injectable pharmaceutical products.
How will this transition impact Pharmaceutics International?
The transition is anticipated to enhance Pii’s capabilities and further its growth potential under Jabil's leadership.
What is the focus of the companies involved in this consortium?
The involved companies primarily focus on growth capital investments, operationally intensive healthcare partnerships, and innovative pharmaceutical solutions.
